Sigilon Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) reported significant progress in its clinical programs and leadership appointments in a recent press release. The company is set to complete its investigation into the clinical hold of its Phase 1/2 trial of SIG-001 by year-end. Additionally, it plans to initiate a Phase 1/2 trial for SIG-005 in MPS-1 in Q4 2021. For Q3 2021, net loss widened to $20.2 million, up from $13.2 million in Q3 2020. Cash reserves stood at $140.4 million. The company appointed Dr. May Orfali as Chief Medical Officer, expected to enhance clinical development strategies.
- Anticipated completion of investigation into SIG-001 clinical hold by year-end.
- Preparations to initiate Phase 1/2 trial of SIG-005 for MPS-1 in Q4 2021.
- Dr. May Orfali's appointment as CMO expected to strengthen clinical strategy.
- Received orphan drug designation for SIG-005, indicating significant market potential.
- Net loss increased to $20.2 million for Q3 2021, wider than $13.2 million in Q3 2020.
- Cash decreased from $202.2 million at year-end 2020 to $140.4 million by September 30, 2021.
- R&D expenses rose to $16.6 million, up from $13.4 million year-over-year, indicating increasing operational costs.
Company expects to complete its investigation of the clinical hold on its Phase 1/2 trial of SIG-001
in hemophilia A by year-end
On track to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021
Company appoints May Orfali, M.D., M.B.A, as Chief Medical Officer
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the third quarter ended September 30, 2021 as well as certain other business highlights.
“In the third quarter, we made meaningful progress advancing the development of our lysosomal disease program, while strengthening our leadership team to bolster our clinical and R&D capabilities,” said Rogerio Vivaldi, M.D., President and CEO of Sigilon. “Most recently, we welcomed Dr. May Orfali as Chief Medical Officer. We believe May’s insights will have an immediate impact on our Company’s operations and overall development strategy.”
Continued Dr. Vivaldi: “We remain committed to working with regulators to resolve the clinical hold on our Phase 1/2 trial of SIG-001 in hemophilia A and we anticipate completing our thorough investigation by year-end. In parallel, we have made meaningful progress advancing the development of our lysosomal disease program. Of note, our CTA for SIG-005 in MPS-1 was accepted in the UK and we received our second orphan drug designation for this product candidate, underscoring the global need for new treatment options to manage patients with this rare lysosomal disease. Each of these milestones represents an important step in advancing the development of SIG-005.”
Recent Program Highlights
- In July 2021, the Phase 1/2 study of SIG-001 in hemophilia A was placed on clinical hold by the U.S. Food and Drug Administration (FDA). To date, three patients have been dosed with SIG-001 and are continuing to be monitored by study protocol. The clinical hold was initiated following Sigilon’s submission of a serious adverse event (SAE) and temporary enrollment halt to the FDA and other regulatory agencies relating to the development of inhibitors to FVIII in the third patient. The Company expects to complete its investigation of this event before year-end.
- In September 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom accepted the Company’s Clinical Trial Application (CTA) for SIG-005 in mucopolysaccharidosis type I (MPS-1). In addition, the Company filed a CTA in Brazil for SIG-005 in July 2021 and plans to submit an Investigational New Drug Application to the FDA.
- In October 2021, the European Commission granted orphan drug designation to SIG-005 for the treatment of MPS-1.
- Sigilon presented results from several ongoing preclinical studies in the rare lysosomal diseases MPS-1, MPS-2 and MPS-6 at the 16th International Symposium on MPS and Related Diseases (MPS 2021), which took place July 23 – 25, 2021.
Corporate Updates
- May Orfali, M.D., M.B.A., will join the Company as an EVP and Chief Medical Officer (CMO), effective as of November 29, 2021, to lead the Company’s clinical development and medical affairs functions. Dr. Orfali has over 25 years of drug development experience across all phases of clinical development. Prior to joining Sigilon, Dr. Orfali held a number of executive leadership roles, most recently as president of Rare Disease & Oncology Consulting, LLC where she served as interim CMO for multiple small biotech companies in the rare disease and oncology space. Prior to that, she was the CMO of CANbridge Life Sciences, where she led the clinical development and medical affairs group, and Executive Director, Global Product Development at Pfizer, where she was responsible for patient-focused drug development across multiple rare disease assets including hemophilia.
- Susan Drapeau, Ph.D., was promoted from SVP, Head of Pre-clinical Development to EVP, Chief Pre-clinical Operations Officer. Dr. Drapeau has over 20 years of industry experience in cell therapy, biologics, biomaterials, protein therapies and medical device development.
- In July, Ajay Rai, M.B.A., joined the Company as SVP, Head of Business Development. Mr. Rai brings over two decades of business development, finance and partnering experience in the life sciences industry to Sigilon.
- Sigilon has initiated a search for a full-time Chief Financial Officer (CFO). In the meantime, the Company has entered into a consulting agreement with Michael Wyzga, M.B.A. Previously, Mr. Wyzga served in various senior management positions, including CFO at Genzyme Corporation for over a decade.
Anticipated Milestones
- Sigilon expects to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021.
- The Company expects to provide up to 12 months of follow-up data for three patients from the Phase 1/2 safety and dose-ranging study of SIG-001 in severe to moderate-severe hemophilia A in the fourth quarter of 2021.
Financial Results
- Cash Position: Cash was
$140.4 million as of September 30, 2021 compared to$202.2 as of December 31, 2020. - R&D Expenses: Research and development expenses were
$16.6 million for the third quarter of 2021 compared to$13.4 million for the third quarter of 2020. The increase in research and development expenses was primarily related to ongoing platform, pipeline, and development activities related to Sigilon’s SIG-005 and SIG-007 programs, which received orphan drug designation in December 2020 and March 2021, respectively. During the third quarter of 2021, expenses increased for SIG-005 as the Company’s CTA was accepted by MHRA in the United Kingdom and the Company filed a CTA in Brazil. The Company expects to initiate a Phase 1/2 trial of SIG-005 for MPS-1 in the fourth quarter of 2021. Personnel expenses increased primarily as a result of the increase in headcount in Sigilon’s research and development function and increases in stock-based compensation. These increases were partially offset by a reduction of$2.9 million associated with Sigilon’s SIG-002 program. The decrease in SIG-002 related expenses was due to timing of preclinical activities. - G&A Expenses: General and administrative expenses were
$5.0 million for the third quarter of 2021 compared to$3.3 million for the third quarter of 2020. The increase in general and administrative expenses was driven by a$1.2 million increase in personnel expenses, which was primarily the result of an increase in headcount and an increase in stock-based compensation. Stock-based compensation expense increased to$1.2 million from$0.4 million for the three months ended September 30, 2020. In addition, the increase in general and administrative expenses was driven by a$0.8 million in the expansion of personnel and internal infrastructure to support our operations as a public company. - Net Loss: Net loss was
$20.2 million for the third quarter ended September 30, 2021 compared to$13.2 million for the same period of 2020.
About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Forward-Looking Statements
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. These forward-looking statements address various matters, including the timing for the initiation of our Phase 1/2 clinical trial of SIG-005 in MPS-1, the impact and timing of our CMO hiring, the timing of our investigation of the clinical hold of our Phase 1/2 clinical study of SIG-001 in Hemophilia A including the timing of our meeting with the FDA and other regulatory agencies and anticipated follow-up data for three patients from our Phase 1/2 clinical study of SIG-001. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, that favorable preclinical results are not predictive of clinical trial results, our ability to resolve the clinical hold on SIG-001, the FDA or other regulators may request additional preclinical studies or clinical trials beyond those that we currently anticipate, manufacturing changes may not have the desired effect, and the risks identified under the heading “Risk Factors” in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, and filed with the Securities and Exchange Commission (the “SEC”), as well as the other information we file with the SEC. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Sigilon Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(Unaudited)
| September 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash | $ | 140,393 | $ | 202,229 | ||||
| Accounts receivable (inclusive of | 27 | 177 | ||||||
| Prepaid expenses and other current assets | 3,531 | 1,729 | ||||||
| Restricted cash—current | 75 | 75 | ||||||
| Total current assets | 144,026 | 204,210 | ||||||
| Property and equipment, net | 3,910 | 2,991 | ||||||
| Right‑of‑use assets | 14,568 | 16,731 | ||||||
| Restricted cash | 1,293 | 1,118 | ||||||
| Total assets | $ | 163,797 | $ | 225,050 | ||||
| Liabilities, convertible preferred stock and stockholders’ equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 3,226 | $ | 1,988 | ||||
| Accrued expenses and other current liabilities | 7,657 | 7,892 | ||||||
| Lease liabilities, current portion | 5,673 | 5,361 | ||||||
| Deferred revenue from related party, current portion | 24,310 | 31,777 | ||||||
| Total current liabilities | 40,866 | 47,018 | ||||||
| Lease liability, net of current portion | 9,442 | 11,893 | ||||||
| Long‑term debt, net of discount | 20,009 | 19,807 | ||||||
| Other liabilities | 176 | 176 | ||||||
| Total liabilities | $ | 70,493 | $ | 78,894 | ||||
| Stockholders’ equity | ||||||||
| Common stock, par value | 32 | 31 | ||||||
| Preferred stock, par value | — | — | ||||||
| Additional paid‑in capital | 288,766 | 282,053 | ||||||
| Accumulated deficit | (195,494 | ) | (135,928 | ) | ||||
| Total stockholders’ equity | 93,304 | 146,156 | ||||||
| Total liabilities, convertible preferred stock and stockholders’ equity | $ | 163,797 | $ | 225,050 | ||||
Sigilon Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited, in thousands, except per share data)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenue | ||||||||||||||||
| Collaboration revenue | $ | 1,947 | $ | 4,201 | $ | 7,609 | $ | 9,618 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 16,645 | 13,425 | 50,381 | 39,151 | ||||||||||||
| General and administrative | 5,041 | 3,334 | 15,572 | 9,023 | ||||||||||||
| Total operating expenses | 21,686 | 16,759 | 65,953 | 48,174 | ||||||||||||
| Loss from operations | (19,739 | ) | (12,558 | ) | (58,344 | ) | (38,556 | ) | ||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest income | 56 | 30 | 212 | 268 | ||||||||||||
| Interest expense | (499 | ) | (293 | ) | (1,481 | ) | (697 | ) | ||||||||
| Other income (expense) | 26 | (20 | ) | 47 | (47 | ) | ||||||||||
| Change in fair value of preferred stock warrant liability | — | (10 | ) | — | (44 | ) | ||||||||||
| Loss on extinguishment of debt | — | (343 | ) | — | (343 | ) | ||||||||||
| Total other expense, net | (417 | ) | (636 | ) | (1,222 | ) | (863 | ) | ||||||||
| Net loss and comprehensive loss | $ | (20,156 | ) | $ | (13,194 | ) | $ | (59,566 | ) | $ | (39,419 | ) | ||||
| Net loss per share attributable to common stockholders—basic and diluted | $ | (0.63 | ) | $ | (2.47 | ) | $ | (1.88 | ) | $ | (7.56 | ) | ||||
| Weighted average common stock outstanding—basic and diluted | 32,055,551 | 5,338,177 | 31,707,068 | 5,214,818 | ||||||||||||
SOURCE: Sigilon Therapeutics, Inc.
Investor Contact
Robert Windsor, Jr., J.D.
VP, Head of Investor Relations
Sigilon Therapeutics
robert.windsor@sigilon.com
617-586-3837
Media Contacts
Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349
Brandon Hagen
Manager, Communications
Sigilon Therapeutics
brandon.hagen@sigilon.com
617-586-2851
FAQ
What are the latest updates on SGTX's clinical trials?
What is the financial status of Sigilon Therapeutics as of Q3 2021?
Who has been appointed as Chief Medical Officer of Sigilon?
Has SGTX received any orphan drug designations recently?
